infection-control-2016_scientifictracks-workshop

4 / 25

Page 33
Notes:
conferenceseries.com
November 28-29, 2016 Valencia, Spain
4th World Congress on
Infection Prevention and Control
Volume 4, Issue 8 (Suppl) J Infect Dis Ther 2016
ISSN: 2332-0877, JIDT an open access journal Infection Control 2016
November 28-29, 2016
Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV):Asystematic
review and meta-analysis
Alaa Badawi1 and Seung Gwan Ryoo 2
1Public Health Agency of Canada, Canada
2University of Toronto, Canada
Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with life threatening severe illnesses and a mortality
rate of ~35%, particularly in patients with underlying comorbidities. Systematic analysis of 637 MERS-CoV cases suggests
that diabetes and hypertension are equally prevalent in ~50% of the patients. Cardiac diseases and obesity are present, respectively in
30% and 16% of the cases. These conditions down-regulate the synthesis of pro-inflammatory cytokines and impair the host's innate
and humoral immune systems. In conclusion, the protection against MERS-CoV and other respiratory infections can be improved if
public health vaccination strategies are tailored to target persons with chronic disorders.
Biography
Alaa Badawi is affiliated to the Public Health Agency of Canada, Canada.
Alaa Badawi et al., J Infect Dis Ther 2016, 4:8 (Suppl)